Encinitas, CA, United States of America

Matthew Robert Janes

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Araxes Pharma LLC. Active years: 2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthew Robert Janes. Retrieved from https://idiyas.com/inventor/matthew-robert-janes

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 36(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Matthew Robert Janes

Introduction

Matthew Robert Janes is a notable inventor based in Encinitas, California. He has made significant strides in the field of cancer treatment through his innovative research and development. His work primarily focuses on combination therapies that target specific genetic mutations associated with cancer.

Latest Patents

Matthew holds a patent for "Combination therapies for treatment of cancer." This patent specifically addresses therapies for cancers associated with mutations in the KRAS gene. The compositions he has developed comprise therapeutic agents aimed at effectively treating these specific cancers.

Career Highlights

Matthew is currently associated with Araxes Pharma LLC, where he continues to contribute to advancements in cancer treatment. His dedication to research and innovation has positioned him as a key figure in the pharmaceutical industry.

Collaborations

Matthew has collaborated with esteemed colleagues, including Matthew Patricelli and Liansheng Li. These partnerships have further enhanced the scope and impact of his research.

Conclusion

Matthew Robert Janes exemplifies the spirit of innovation in the medical field, particularly in cancer treatment. His contributions through patents and collaborations highlight the importance of targeted therapies in improving patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…